Navigation Links
OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer
Date:5/30/2008

PORTLAND, Ore. Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.

The research involved men with androgen-independent prostate cancer that has metastasized, meaning their cancer has spread beyond the prostate and is not longer responding to hormonal therapies. This is the most advanced form of prostate cancer. Prostate cancer is the most common type of cancer in men in the United States, where it is responsible for more male deaths than any other cancer, except lung cancer.

"We are showing solid activity that this drug shows promise," said Tomasz Beer, M.D., principal investigator. He is the Grover C. Bagby Endowed Chair for Cancer Research, director of the Prostate Cancer Research Program at the OHSU Cancer Institute and associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.

This research will be presented Saturday, May 31 at 8 a.m. at the annual American Association of Clinical Oncology in Chicago.

Of the 37 study participants taking the Sagopilone and prednisone long enough to be evaluated, the majority showed positive results in the reduction of their prostate specific antigens, or PSA. PSA is often elevated in the presence of prostate cancer.

During the three-month trial thirteen study participants had a more than 50 percent reduction in their PSA; 23 showed a 30 percent reduction; one who had radiographic measurable disease showed complete response; and four had unconfirmed prostate response. A 30 percent reduction in PSA levels in three months is a strong indicator of survival.

Sagopilone, a fully synthetic derivation, is a new class of drug that inhibits growth and the spread of malignant cell, similar to docetaxel, which has been the gold standard for this type of hormone independent prostate cancer. Docetaxel, however, it is not a cure and not all patients benefit from it. For this reason, Beer and colleagues are committed to searching for new drugs that will be effective against advanced prostate cancer.

"We look forward to completing this study and to the further investigation of Sagopilone as a new treatment option for men with advanced prostate cancer," said Beer.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology: